◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › ZYME

Zymeworks Inc. (ZYME) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-10

Zymeworks Inc. (ZYME) operates in the Biotechnology industry and is headquartered in Middletown, United States with about 243 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ZYME reported $106M in revenue and ($81M) in net income.

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.

Interactive charts & full statements → Open the ZYME valuation workbench →

ZYME Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$106M$76M$76M$412M
Operating Income (EBIT)($92M)($120M)($138M)$130M
Net Income($81M)($123M)($119M)$124M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ZYME Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$2M$2M$28M$49M$27M
Operating Income (EBIT)($47M)($44M)($22M)($1M)($26M)
Net Income($44M)($41M)($20M)$2M($23M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ZYME Free Cash Flow History

ZYME Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$346M$463M$581M$649M
Total Liabilities$78M$124M$116M$156M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ZYME viewer.

Other Companies in Biotechnology

← ZYBTAll stocks

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.